SCHEMBL6032387

SCHEMBL6032387

Cc1ccc2c(c1)CCCN2C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
MAPT P10636 3/20 0.60
TP53 P04637 2/20 0.60
ALDH1A1 P00352 2/20 0.60
KDM4E B2RXH2 2/20 0.60
ALOX15 P16050 1/20 0.60
HSD17B10 Q99714 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.56
HTR2A P28223 2/20 0.55
HTR2C P28335 2/20 0.55
LMNA P02545 3/20 0.54
P2RX1 P51575 1/20 0.54
MAPK1 P28482 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
RIPK1 Q13546 1/20 0.51
USP2 O75604 1/20 0.50
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6032679 0.82 MEN1 (0.61) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL13528800 0.81 BRAF (0.59) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL2481583 0.81 HTR2A (0.64) MEN1KMT2AMAPTTP53SMN1; SMN2
SCHEMBL6007365 0.81 MEN1 (0.63) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL4870805 0.81 HTR2A (0.63) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL9056673 0.81 HTR2C (0.57) MEN1KMT2AMAPTSMN1; SMN2HTR2A
SCHEMBL14458188 0.80 NPC1 (0.67) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL6006626 0.80 MEN1 (0.57) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL25991287 0.80 MAPT (0.61) MEN1KMT2AMAPTTP53ALDH1A1
SCHEMBL13536431 0.78 HTR2C (0.65) MEN1KMT2AMAPTTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637521-B1 NOVEL TRICYCLIC HETEROCYCLE COMPOUND ONO PHARMACEUTICAL CO (JP) 2013-06-19 EP disclosed
US-20060154944-A1 Novel tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154944-A1 Novel tricyclic heterocycle compound CYP11B1, CYP11B2, HCCS MEN1 1017/4885KMT2A 2539/4885MAPT 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.